XML 51 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Intangible Assets, net (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
A summary of the activity impacting goodwill is presented below (in thousands):
Balance as of December 31, 2023
$416,821 
Adjustment
— 
Balance as of December 31, 2024
$416,821 
Schedule of Finite-Lived Intangible Assets Accumulated Amortization and Weighted Average Useful Lives The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of December 31, 2024 (in thousands).
Weighted Average Useful Life (in years)
Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Auto-Injector technology platform7$402,000 $149,592 $252,408 
XYOSTED proprietary product10136,200 35,478 100,722 
Total finite-lived intangibles, net(1)
$538,200 $185,070 $353,130 
ATRS-1902 (IPR&D)Indefinite48,700 
Total intangibles, net
$401,830 
(1)    An impairment charge of $2.5 million was recognized during the year ended December 31, 2023 resulting in the full impairment of the TLANDO product rights intangible asset. The impairment charge resulted from the notice of termination of the TLANDO license agreement provided to Lipocine in September 2023, effective January 31, 2024, and is included in amortization of intangibles in our consolidated statements of income.
Schedule of Indefinite-Lived Intangible Assets The following table shows the cost, accumulated amortization and weighted average useful life in years for our acquired intangible assets as of December 31, 2024 (in thousands).
Weighted Average Useful Life (in years)
Gross Carrying ValueAccumulated AmortizationNet Carrying Value
Auto-Injector technology platform7$402,000 $149,592 $252,408 
XYOSTED proprietary product10136,200 35,478 100,722 
Total finite-lived intangibles, net(1)
$538,200 $185,070 $353,130 
ATRS-1902 (IPR&D)Indefinite48,700 
Total intangibles, net
$401,830 
(1)    An impairment charge of $2.5 million was recognized during the year ended December 31, 2023 resulting in the full impairment of the TLANDO product rights intangible asset. The impairment charge resulted from the notice of termination of the TLANDO license agreement provided to Lipocine in September 2023, effective January 31, 2024, and is included in amortization of intangibles in our consolidated statements of income.
Schedule of Finite-Lived Intangible Assets, Estimated Future Amortization Expense
Estimated future annual amortization of finite-lived intangible assets is shown in the following table (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset impairments, among other factors.
Year
Amortization Expense
2025
$71,049 
2026
71,049 
2027
71,049 
2028
71,049 
2029
36,313 
Thereafter32,621 
Total$353,130